IRIS UniCatt

Mercuri, Eugenio Maria
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 19.703
EU - Europa 16.528
AS - Asia 16.095
SA - Sud America 3.263
AF - Africa 436
OC - Oceania 54
Continente sconosciuto - Info sul continente non disponibili 15
Totale 56.094
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 19.013
SG - Singapore 7.532
DE - Germania 4.528
IT - Italia 3.506
CN - Cina 3.467
BR - Brasile 2.642
SE - Svezia 1.779
VN - Vietnam 1.486
FR - Francia 1.445
NL - Olanda 955
GB - Regno Unito 777
IE - Irlanda 729
UA - Ucraina 706
IN - India 584
ID - Indonesia 496
JP - Giappone 488
FI - Finlandia 468
RU - Federazione Russa 420
BD - Bangladesh 409
HK - Hong Kong 365
CA - Canada 347
PL - Polonia 340
AR - Argentina 243
TR - Turchia 228
MX - Messico 185
IQ - Iraq 175
KR - Corea 173
ES - Italia 160
ZA - Sudafrica 136
AT - Austria 123
BE - Belgio 101
EC - Ecuador 91
PK - Pakistan 90
SA - Arabia Saudita 86
CZ - Repubblica Ceca 85
CO - Colombia 75
CH - Svizzera 72
IR - Iran 71
LT - Lituania 60
MA - Marocco 56
VE - Venezuela 54
PH - Filippine 49
UZ - Uzbekistan 45
EG - Egitto 44
AE - Emirati Arabi Uniti 43
CL - Cile 42
IL - Israele 42
AU - Australia 41
KE - Kenya 39
PY - Paraguay 39
PE - Perù 37
CI - Costa d'Avorio 36
JO - Giordania 33
RO - Romania 33
TN - Tunisia 31
PA - Panama 29
RS - Serbia 25
JM - Giamaica 23
KZ - Kazakistan 23
BG - Bulgaria 22
PT - Portogallo 22
DZ - Algeria 21
GR - Grecia 21
MY - Malesia 21
NP - Nepal 21
OM - Oman 20
UY - Uruguay 20
AZ - Azerbaigian 17
CR - Costa Rica 17
HN - Honduras 17
AL - Albania 16
DK - Danimarca 16
HU - Ungheria 15
NO - Norvegia 15
TH - Thailandia 15
TW - Taiwan 14
BO - Bolivia 13
DO - Repubblica Dominicana 13
HR - Croazia 13
MK - Macedonia 13
NG - Nigeria 13
SK - Slovacchia (Repubblica Slovacca) 13
TT - Trinidad e Tobago 13
BY - Bielorussia 12
KG - Kirghizistan 12
LB - Libano 12
BH - Bahrain 11
PS - Palestinian Territory 11
AM - Armenia 10
ET - Etiopia 10
GT - Guatemala 10
NZ - Nuova Zelanda 9
LK - Sri Lanka 8
MD - Moldavia 8
NI - Nicaragua 8
SN - Senegal 8
A2 - ???statistics.table.value.countryCode.A2??? 7
LV - Lettonia 7
SY - Repubblica araba siriana 7
AO - Angola 6
Totale 55.957
Salva come PNG Salva come JPEG
Città #
Singapore 4.205
Ashburn 2.230
San Jose 2.172
Chandler 2.042
New York 808
Amsterdam 736
Dublin 681
Rome 651
Beijing 636
Frankfurt am Main 615
Los Angeles 600
Ho Chi Minh City 521
Hefei 505
Jakarta 448
Tokyo 439
Munich 433
Lauterbourg 432
Jacksonville 416
Milan 414
San Mateo 375
Hanoi 363
Hong Kong 332
Dallas 289
Boston 278
Warsaw 269
Nanjing 266
São Paulo 266
Wilmington 265
Moscow 235
Chicago 227
Houston 227
Marseille 219
Buffalo 213
Helsinki 198
Ann Arbor 192
Dearborn 188
Santa Clara 181
Nürnberg 177
The Dalles 168
Seoul 162
Woodbridge 160
Tukwila 158
Princeton 157
Seattle 150
Boardman 143
Kent 138
Fairfield 136
Council Bluffs 132
Lawrence 128
London 119
Atlanta 117
Orem 116
Redwood City 114
Brooklyn 113
Montreal 110
Nuremberg 110
Bremen 104
Denver 104
Cattolica 103
Nanchang 98
Paris 97
Chennai 94
Toronto 94
Stockholm 91
Johannesburg 89
Brussels 82
Shanghai 78
Phoenix 76
Poplar 76
Redmond 76
Da Nang 74
Baghdad 73
Lancaster 73
Rio de Janeiro 68
Mexico City 67
Hebei 65
Norwalk 63
Düsseldorf 62
San Francisco 62
Turku 61
Pune 59
Detroit 56
Izmir 56
Augusta 54
Belo Horizonte 54
Haiphong 54
Hangzhou 54
Guangzhou 52
Naples 52
Dhaka 51
Brno 50
Mountain View 50
Shenyang 50
Ankara 49
Florence 49
Lappeenranta 49
Palermo 48
Tianjin 48
Vienna 48
Brasília 47
Totale 29.135
Salva come PNG Salva come JPEG
Nome #
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 962
Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial 682
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 503
Validation and cross-cultural adaptation of the Italian version of the Pediatric Eating Assessment Tool (I-PEDI-EAT-10) in genetic syndromes 406
Tele-riabilitazione con il Training Lettura Ritmica: Applicazione a distanza di un training ritmico-musicale per il potenziamento della lettura nella dislessia evolutiva 391
Oral and Swallowing Abilities Tool (OrSAT) for Type 1 SMA Patients: Development of a New Module 336
Hammersmith Infant Neurological Examination in infants born at term: Predicting outcomes other than cerebral palsy 324
The visual function assessment: from birth to the follow up 314
Reliability of the Performance of Upper Limb assessment in Duchenne muscular dystrophy 312
Visual Function in Children with GNAO1-Related Encephalopathy 288
Cortical visual function in preterm infants in the first year. 277
Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial 274
Neurological examination of preterm infants a term equivalent age 271
Hospital admissions from the emergency department of adult patients affected by myopathies 260
Spinal muscular atrophy 249
Performance of Upper Limb module for Duchenne muscular dystrophy 245
Use of the Hammersmith Infant Neurological Examination in Infants With Cerebral Palsy: A Critical Review of the Literature 241
Prognostic value of EEG performed at term age in preterm infants. 231
Specific Learning Disorders (SLD) and behavior impairment: Comorbidity or specific profile? 231
Neurological examination at 6 to 9 months in infants with cystic periventricular leukomalacia 229
Enhanced human brain associative plasticity in Costello syndrome 229
Visual function at 35 and 40 weeks' postmenstrual age in low-risk preterm infants. 225
Application of a neonatal assessment of visual function in a population of low risk full-term newborn. 217
Assessing floppy infants: a new module 213
Sleep-potentiated epileptiform activity in early thalamic injuries: Study in a large series (60 cases) 210
-Thalamic atrophy in infants with PVL and cerebral visual impairment 206
Oral and Swallowing Abilities Tool (OrSAT) in nusinersen treated patients 204
Crossed cerebellar atrophy of prenatal onset 202
Novel de novo heterozygous loss-of-function variants in MED13L and further delineation of the MED13L haploinsufficiency syndrome 200
Neurological assessment of newborns with spinal muscular atrophy identified through neonatal screening 192
Developmental milestones in type I spinal muscular atrophy 190
Predictive models in SMA II natural history trajectories using machine learning: A proof of concept study 186
External hydrocephalus in discordant birth weight twins: a case report 184
Sleep disturbances in preschool age children with cerebral palsy: a questionnaire study 184
A current approach to heart failure in Duchenne muscular dystrophy 184
Co-occurrence of fragile x syndrome with a second genetic condition: Three independent cases of double diagnosis 184
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial 183
Development of clinical signs in low risk term born infants with neonatal hyperexcitability 183
Longitudinal assessment of perceptual-motor abilities in pre-school preterm children 183
Visual development in prenatal post-haemorragic ventricular dilatation 182
Salbutamol increases survival motor neuron (SMN) transcript levels in leucocytes of spinal muscular atrophy (SMA) patients: relevance for clinical trial design. 181
Experience of a 2-year spinal muscular atrophy NBS pilot study in Italy: towards specific guidelines and standard operating procedures for the molecular diagnosis 180
DMD myogenic cells from urine-derived stem cells recapitulate the dystrophin genotype and phenotype 180
Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian Nationwide Survey 180
Early visual assessment in preterm infants with and without brain lesions: correlation with visual and neurodevelopmental outcome at 12 months. 179
SMN transcript levels in leukocytes of SMA patients determined by absolute real-time PCR. 179
Use of the Hammersmith Infant Neurological Examination in infants with cerebral palsy: a critical review of the literature. 179
Early assessment of visual function in preterm infants: how early is early? 177
Respiratory Needs in Patients with Type 1 Spinal Muscular Atrophy Treated with Nusinersen 177
Broad phenotypic spectrum and genotype-phenotype correlations in GMPPB-related dystroglycanopathies: an Italian cross-sectional study. 176
Early visual and neuro-development in preterm infants with and without retinopathy 176
Age, corticosteroid treatment and site of mutations affect motor functional changes in young boys with Duchenne Muscular Dystrophy 173
Early development in Dravet syndrome; visual function impairment precedes cognitive decline 173
Neuropsychological development in children with Dravet syndrome. 173
Age, corticosteroid treatment and site of mutations affect motor functional changes in young boys with Duchenne Muscular Dystrophy 170
Follow-up to Age 4 Years of Treatment of Type 1 Retinopathy of Prematurity Intravitreal Bevacizumab Injection versus Laser: Fluorescein Angiographic Findings 170
Attention Deficit Hyperactivity Disorder and Cognitive Function in Duchenne Muscular Dystrophy: Phenotype-Genotype Correlation 169
Sleep disturbances in preschool age children with cerebral palsy: a questionnaire study 169
Cardiac Function in Types II and III Spinal Muscular Atrophy: Should We Change Standards of Care? 168
Intragenic KANSL1 mutations and chromosome 17q21.31 deletions: broadening the clinical spectrum and genotype-phenotype correlations in a large cohort of patients 168
Type I SMA “new natural history”: long-term data in nusinersen-treated patients 167
Functional changes in Duchenne muscular dystrophy: a 12-month longitudinal cohort study 166
Assessing Joint Hypermobility in Preschool-Aged Children 166
Onasemnogene abeparvovec in spinal muscular atrophy: predictors of efficacy and safety in naïve patients with spinal muscular atrophy and following switch from other therapies 165
Body mass index in type 2 spinal muscular atrophy: a longitudinal study 165
Antenatal post-hemorragic ventriculomegaly: a prospective follow-up study 165
SMA-miRs (MiR-181a- 5p, -324-5p, and -451a) are overexpressed in spinal muscular atrophy skeletal muscle and serum samples 165
Muscle MRI in Becker muscular dystrophy 164
Early neurodevelopmental characterization in children with cobalamin C/defect 164
Longitudinal Cognitive Assessment in Low-Risk Very Preterm Infants 164
Muscle MRI in Becker muscular dystrophy 163
Sleep disorders in autism spectrum disorder pre-school children: An evaluation using the sleep disturbance scale for children 162
SMA-miRs (MiR-181a- 5p, -324-5p, and -451a) are overexpressed in spinal muscular atrophy skeletal muscle and serum samples 162
Early neurological signs in infants identified through neonatal screening for SMA: do they predict outcome? 161
Mutations in KANSL1 cause the 17q21.31 microdeletion syndrome phenotype 161
Muscle MRI: Out of the tunnel. 159
Perceptual-motor abilities in pre-school preterm children 159
Long Term Memory Profile of Disorders Associated with Dysregulation of the RAS-MAPK Signaling Cascade. 158
Longitudinal evaluation of SMN levels as biomarker for spinal muscular atrophy: results of a phase IIb double-blind study of salbutamol 158
Different trajectories in upper limb and gross motor function in spinal muscular atrophy 158
Gain and loss of upper limb abilities in Duchenne muscular dystrophy patients: A 24-month study 157
Cardiac Function in Types II and III Spinal Muscular Atrophy: Should We Change Standars of Care? 157
Visual processing in Noonan syndrome: dorsal and ventral stream sensitivity 156
Hammersmith Infant Neurological Examination in low-risk infants born very preterm: a longitudinal prospective study 156
Neuropsychological development in children with Dravet syndrome 155
Visual processing in Noonan syndrome: dorsal and ventral stream sensitivity 155
Expanded access program with Nusinersen in SMA type I in Italy: Strengths and pitfalls of a successful experience 155
Age related treatment effect in type II Spinal Muscular Atrophy pediatric patients treated with nusinersen 155
Co-occurrence of fragile x syndrome with a second genetic condition: Three independent cases of double diagnosis 155
Nusinersen in type 1 spinal muscular atrophy: Twelve-month real-world data 154
Sometimes they come back: New and old spinal muscular atrophy adults in the era of nusinersen 153
Contactless: a new personalised telehealth model in chronic pediatric diseases and disability during the COVID-19 era 153
A critical review of functional assessment tools for upper limbs in Duchenne muscular dystrophy 152
Experience of a 2-year spinal muscular atrophy NBS pilot study in Italy: Towards specific guidelines and standard operating procedures for the molecular diagnosis 151
Respiratory function and therapeutic expectations in DMD: Families experience and perspective 151
Risdiplam in types 2 and 3 spinal muscular atrophy: A randomised, placebo-controlled, dose-finding trial followed by 24 months of treatment 150
Visual function assessment in late-preterm newborns. 150
Upper Girdle Imaging in Facioscapulohumeral Muscular Dystrophy 150
Can the CHOP-INTEND be used as An Outcome Measure in the First Months of Age? Implications for Clinical Trials and Real World Data 149
FGF17, a gene involved in cerebellar development, is downregulated in a patient with Dandy-Walker malformation carrying a de novo 8p deletion 149
Totale 20.779
Salva come PNG Salva come JPEG
Categoria #
all - tutte 236.129
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 236.129
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.612 222 137 75 185 141 104 52 418 144 178 471 485
2022/20236.233 714 766 454 927 398 780 377 543 759 89 255 171
2023/20244.514 185 919 143 293 171 711 474 202 108 229 449 630
2024/20259.194 211 238 670 445 775 442 427 419 1.293 772 1.897 1.605
2025/202626.058 3.252 800 1.654 3.072 4.334 2.861 4.006 1.138 1.370 1.555 1.029 987
2026/2027513 513 0 0 0 0 0 0 0 0 0 0 0
Totale 56.804